Dr. Shah Highlights Immunotherapy for Esophageal Cancer

Manish A. Shah, MD
Published: Wednesday, Jul 18, 2018



Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, highlights immunotherapy for esophageal cancer.

In general, the prognosis is not very optimistic for patients with metastatic disease—a significant amount will die within 1 year. There are very few targeted therapies in esophageal cancer, and most patients do not receive treatment after second-line therapy, Shah says.

However, recent data suggest that the PD-1 inhibitor pembrolizumab (Keytruda) can have modest efficacy in the third-line setting for patients with adenocarcinoma and squamous cell carcinoma. The most compelling aspect of the findings, Shah adds, was the durability of the responses. Patients who responded to immunotherapy could have increased overall survival of up to 1 year or longer.

Data from the phase Ib KEYNOTE-28 trial indicate that pembrolizumab induced an overall response rate of 30% (95% CI, 13%-53%) in patients with PD-L1–positive advanced esophageal carcinoma.
SELECTED
LANGUAGE


Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, highlights immunotherapy for esophageal cancer.

In general, the prognosis is not very optimistic for patients with metastatic disease—a significant amount will die within 1 year. There are very few targeted therapies in esophageal cancer, and most patients do not receive treatment after second-line therapy, Shah says.

However, recent data suggest that the PD-1 inhibitor pembrolizumab (Keytruda) can have modest efficacy in the third-line setting for patients with adenocarcinoma and squamous cell carcinoma. The most compelling aspect of the findings, Shah adds, was the durability of the responses. Patients who responded to immunotherapy could have increased overall survival of up to 1 year or longer.

Data from the phase Ib KEYNOTE-28 trial indicate that pembrolizumab induced an overall response rate of 30% (95% CI, 13%-53%) in patients with PD-L1–positive advanced esophageal carcinoma.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x